We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop New Modules for Live Cell Imaging

By Biotechdaily staff writers
Posted on 09 Jun 2006
A collaboration to develop innovative new fluorescence-detection modules for integration with the Cell-IQ live-cell culturing and analysis system of Chip-Man Technologies Ltd. More...
(Tampere, Finland) has been announced by the company and by ArcDia Ltd. (Turku, Finland).

The new modules will be a first in live-cell imaging, enabling simultaneous measurement and analysis of cell events using both phase contrast and living dyes within the same culture under incubation.

Juha Korpinen, CEO, Chip-Man Technologies, said, "This development will greatly enhance the capabilities of the Cell-IQ to enable even more detailed information to be extracted from living cells. Professors Erkki Soini, Juhani Soini, and colleagues are widely respected in the field of fluorescence detection. We are very fortunate to have such key expertise available within our local academic institutions.”

Cell-IQ represents a major breakthrough in cell analysis by enabling real time monitoring of all morphologic and physiologic changes in cell lines, primary cells, co-cultures and monolayer tissue models. The Cell-IQ software "learns” to recognize and record cellular change and to output these results as real-time moving images and simple multi-parameter graphics.

The addition of a fluorescence detection module will enable the Cell IQ to identify specific siRNA and cDNA transcripts. This will allow them to be closely monitored and the resulting morphologic changes recorded within the population. Thus the measurement of the true rate of cellular stimulation to specific drugs will be possible. In addition researchers can select out those fluorophores that minimally affect cells or have a synergistic or antagonistic effect on target drugs, enabling better optimization and control of cell based experimentation.



Related Links:
Chip-Man Technologies

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.